Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma associated with topical TCI use in adults and children, separately. A cohort study in Denm...

Full description

Saved in:
Bibliographic Details
Published in:Clinical epidemiology 2021-01, Vol.13, p.1141-1153
Main Authors: Arana, Alejandro, Pottegård, Anton, Kuiper, Josephina G, Booth, Helen, Reutfors, Johan, Calingaert, Brian, Lund, Lars Christian, Crellin, Elizabeth, Schmitt-Egenolf, Marcus, Kaye, James A, Gembert, Karin, Rothman, Kenneth J, Kieler, Helle, Dedman, Daniel, Houben, Eline, Gutiérrez, Lia, Hallas, Jesper, Perez-Gutthann, Susana
Format: Article
Language:English
Subjects:
Age
Cancer
Clinical medicine
Cohort analysis
Corticosteroids
cutaneous T-cell lymphoma
database study
Drug dosages
Epidemiology
Ethics
Hypothesis testing
Lymphoma
malignant melanoma
Medical records
Medicin och hälsovetenskap
Melanoma
Non-Hodgkin's lymphomas
non-melanoma skin cancer
Oncology, Experimental
Original Research
Pathology
Patients
Pimecrolimus
Risk factors
Skin cancer
Steroids
T cells
Tacrolimus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma associated with topical TCI use in adults and children, separately. A cohort study in Denmark, Sweden, UK, and the Netherlands was conducted. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for nonmelanoma skin cancer (NMSC), melanoma, cutaneous T-cell lymphoma (CTCL), non-Hodgkin lymphoma (NHL) excluding CTCL, and Hodgkin lymphoma (HL) in new users of TCIs versus users of moderate/high-potency topical corticosteroids. The study included 126,908/61,841 adults and 32,605/27,961 children initiating treatment with tacrolimus/pimecrolimus, respectively. Follow-up was ≥10 years for 19% of adults and 32% of children. Incidence rate ratios and (95% confidence intervals) for tacrolimus versus corticosteroid users in adults were
ISSN:1179-1349
1179-1349
DOI:10.2147/CLEP.S331287